ChromaDex Corporation (CDXC) insider have most recently took part in a trading activity. On Aug 25, 2017 Allen Stephen R., Director bought 2,000 shares having total worth of $6,620 at the price of $3.31 per share, following the transaction a total of 7,000 shares owned by Allen Stephen R.. Before this latest buy, Allen Stephen R. purchased CDXC at 2 other times during the past twelve months, for a total investment of $15,220 at an average of $3.01 per share.
The stock has experienced a total of 3 insider trades in the past three months. These trades include 3 buy trades. Furthermore, over the past 12 months , the stock was traded 10 times by insiders. an employee of the company was the buyer in 10 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
ChromaDex Corporation (CDXC) last announced its earnings results on Aug 10, 2017. The company reported -0.05 earnings per share (EPS) for the quarter, lower than the consensus estimate of 0.04 by $0.09. The company had revenue of $5 million for the quarter, compared to the consensus estimate of $11 million. During the same quarter in the previous year, the company posted 0.01 earnings per share. The company’s revenue for the quarter was down 40% on a year-over-year basis.
|earnings per share||-0.05||-0.05||-0.06||-0.03||0.01||0.01||0.01||0.00||-0.01|
ChromaDex Corporation was originally formed as a California Corporation on February 19, 2000. On April 23, 2003, ChromaDex acquired the research and development group of natural product experienced chemists of Napro Biotherapeutics (currently Tapestry Pharmaceuticals) in a newly-formed, wholly-owned subsidiary of ChromaDex named Chromadex Analytics, Inc., a Nevada Corporation. The Company and its wholly owned subsidiaries are an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The Company supplies ingredients, phytochemical reference standards, and related phytochemical products and services. It recently acquired Spherix Consulting, Inc., which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks. Current products and services provided are: Dietary supplement and food ingredients, Supply of reference standards, materials & kits, Supply of fine chemicals and phytochemicals, Contract services, Consulting services and Process development. The Company use international distributors to market and sell to several foreign countries or markets. Its sales model for products and services is based on direct, inside technical sales. The Company’s hire technical sales staff with appropriate scientific background in chemistry, biology, biochemistry or other related scientific fields. Some of its operations are subject to regulation by various United States federal agencies and similar state and international agencies, including the FDA, the Federal Trade Commission, the Department of Commerce, the Department of Transportation, the Department of Agriculture and other state and international agencies.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018